T cells with high-affinity T cell receptors (TCRs) for a foreign peptide–major histocompatibility complex (pMHC) appear to be negatively selected, even though they have never seen the foreign antigen.

Over the past two decades, antibodies have seized many opportunities—which is to say, there has been a proliferation of therapeutic antibodies that can selectively bind to disease-associated antigens.

Nanovials are emerging as an accessible platform for performing single-cell functional screening leveraging standard instrumentation, such as flow cytometers and microfluidic single-cell sequencing ...

Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Oxford and London, UK – 09 June 2021. Enara Bio, a biotechnology company ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced its 2023 roadmap of new discovery technologies and services across a range of biologic modalities. Alloy will ...

KNOXVILLE, Tenn. (WATE) — Personal information of more than 170,000 retired State of Tennessee employees and/or their beneficiaries was accessed in a hack in May. Tennessee Consolidated Retirement ...